Clinical Trial Update: A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing QL1207H Injection to aflibercept for neovascular age-related macular degeneration is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)
• QL1207H Injection

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Neovascular Age-Related Macular Degeneration (nAMD) | Phase 3 | Status: NOT_YET_RECRUITING